Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis.

Racca V, Rovaris M, Cavarretta R, Vaini E, Toccafondi A, Di Rienzo M.

J Cent Nerv Syst Dis. 2019 May 16;11:1179573519849945. doi: 10.1177/1179573519849945. eCollection 2019.

2.

A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis.

Piancone F, Saresella M, Marventano I, La Rosa F, Caputo D, Mendozzi L, Rovaris M, Clerici M.

J Immunol. 2019 Jul 1;203(1):76-83. doi: 10.4049/jimmunol.1801625. Epub 2019 May 29.

PMID:
31142599
3.

Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis.

Di Tella S, Pagliari C, Blasi V, Mendozzi L, Rovaris M, Baglio F.

J Telemed Telecare. 2019 May 27:1357633X19850381. doi: 10.1177/1357633X19850381. [Epub ahead of print] No abstract available.

PMID:
31132909
4.

Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study.

Groppo E, Signori A, Sormani MP, Grosso C, Mantia L, Cattaneo D, Rovaris M.

Mult Scler J Exp Transl Clin. 2019 Apr 16;5(2):2055217319843673. doi: 10.1177/2055217319843673. eCollection 2019 Apr-Jun.

5.

Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.

Gisondi P, Rovaris M, Piaserico S, Girolomoni G.

Br J Dermatol. 2019 Apr 20. doi: 10.1111/bjd.18015. [Epub ahead of print]

PMID:
31004509
6.

The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment.

Berra E, Bergamaschi R, De Icco R, Dagna C, Perrotta A, Rovaris M, Grasso MG, Anastasio MG, Pinardi G, Martello F, Tamburin S, Sandrini G, Tassorelli C.

Front Hum Neurosci. 2019 Feb 12;13:31. doi: 10.3389/fnhum.2019.00031. eCollection 2019.

7.

Longitudinal associations between mindfulness and well-being in people with multiple sclerosis.

Pagnini F, Cavalera C, Rovaris M, Mendozzi L, Molinari E, Phillips D, Langer E.

Int J Clin Health Psychol. 2019 Jan;19(1):22-30. doi: 10.1016/j.ijchp.2018.11.003. Epub 2018 Dec 5.

8.

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.

Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, Ferrucci S, Pepe P, Liberati S, Pigatto PD, Offidani A, Martina E, Girolomoni G, Rovaris M, Foti C, Stingeni L, Cristaudo A, Canonica GW, Nettis E, Asero R.

J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924. doi: 10.1111/jdv.15350. Epub 2018 Dec 7.

PMID:
30451325
9.

Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial.

Jonsdottir J, Gervasoni E, Bowman T, Bertoni R, Tavazzi E, Rovaris M, Cattaneo D.

Front Neurol. 2018 Sep 28;9:800. doi: 10.3389/fneur.2018.00800. eCollection 2018.

10.

A simple and universal enzyme-free approach for the detection of multiple microRNAs using a single nanostructured enhancer of surface plasmon resonance imaging.

Sguassero A, Artiga Á, Morasso C, Jimenez RR, Rapún RM, Mancuso R, Agostini S, Hernis A, Abols A, Linē A, Gualerzi A, Picciolini S, Bedoni M, Rovaris M, Gramatica F, de la Fuente JM, Vanna R.

Anal Bioanal Chem. 2019 Mar;411(9):1873-1885. doi: 10.1007/s00216-018-1331-0. Epub 2018 Aug 28.

PMID:
30155701
11.

Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues".

Cattaneo D, Gervasoni E, Pupillo E, Bianchi E, Agostini M, Rovaris M, Aprile I, Montesano A, Beghi E.

Arch Phys Med Rehabil. 2018 Aug;99(8):1688-1689. doi: 10.1016/j.apmr.2018.04.001. No abstract available.

PMID:
30053989
12.

Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study.

Gervasoni E, Bove M, Sinatra M, Grosso C, Rovaris M, Cattaneo D, Merati G.

Mult Scler Relat Disord. 2018 Aug;24:85-90. doi: 10.1016/j.msard.2018.06.003. Epub 2018 Jun 27.

PMID:
29982110
13.

Pediatric CD8+/CD56+ mycosis fungoides with cytotoxic marker expression: A variant with indolent course.

Rovaris M, Colato C, Girolomoni G.

J Cutan Pathol. 2018 Oct;45(10):782-785. doi: 10.1111/cup.13317. Epub 2018 Jul 24.

PMID:
29968317
14.

Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.

Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, Cavarretta R, Mantero V, Costantini G, D'Ambrosio V, Zaffaroni M, Ghezzi A, Perini P, Rossi S, Bertolotto A, Rottoli MR, Rovaris M, Balgera R, Cavalla P, Montomoli C, Bergamaschi R.

J Neurol. 2018 Aug;265(8):1850-1859. doi: 10.1007/s00415-018-8916-6. Epub 2018 Jun 14.

PMID:
29948245
15.

Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis.

Piancone F, Saresella M, Marventano I, La Rosa F, Santangelo MA, Caputo D, Mendozzi L, Rovaris M, Clerici M.

Front Immunol. 2018 May 4;9:983. doi: 10.3389/fimmu.2018.00983. eCollection 2018.

16.

Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.

Tavazzi E, Bergsland N, Cattaneo D, Gervasoni E, Laganà MM, Dipasquale O, Grosso C, Saibene FL, Baglio F, Rovaris M.

J Neurol. 2018 Jun;265(6):1393-1401. doi: 10.1007/s00415-018-8859-y. Epub 2018 Apr 7.

PMID:
29627940
17.

HLA alleles modulate EBV viral load in multiple sclerosis.

Agostini S, Mancuso R, Guerini FR, D'Alfonso S, Agliardi C, Hernis A, Zanzottera M, Barizzone N, Leone MA, Caputo D, Rovaris M, Clerici M.

J Transl Med. 2018 Mar 27;16(1):80. doi: 10.1186/s12967-018-1450-6.

18.

Online meditation training for people with multiple sclerosis: A randomized controlled trial.

Cavalera C, Rovaris M, Mendozzi L, Pugnetti L, Garegnani M, Castelnuovo G, Molinari E, Pagnini F.

Mult Scler. 2019 Apr;25(4):610-617. doi: 10.1177/1352458518761187. Epub 2018 Feb 27.

PMID:
29485319
19.

Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke.

Beghi E, Gervasoni E, Pupillo E, Bianchi E, Montesano A, Aprile I, Agostini M, Rovaris M, Cattaneo D; NEUROFALL Group.

Arch Phys Med Rehabil. 2018 Apr;99(4):641-651. doi: 10.1016/j.apmr.2017.10.009. Epub 2018 Feb 1.

PMID:
29102438
20.

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M.

Brain. 2017 Nov 1;140(11):2814-2819. doi: 10.1093/brain/awx250.

PMID:
29053836
21.

Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy.

Groppo E, Baglio F, Cattaneo D, Tavazzi E, Bergsland N, Di Tella S, Parelli R, Carpinella I, Grosso C, Capra R, Rovaris M.

Front Neurol. 2017 Sep 19;8:491. doi: 10.3389/fneur.2017.00491. eCollection 2017.

22.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

PLoS One. 2017 Aug 1;12(8):e0180651. doi: 10.1371/journal.pone.0180651. eCollection 2017.

23.

Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.

Agliardi C, Guerini FR, Zanzottera M, Rovaris M, Caputo D, Clerici M.

J Neurol Sci. 2017 Jun 15;377:31-34. doi: 10.1016/j.jns.2017.03.048. Epub 2017 Mar 29.

PMID:
28477703
24.

Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis.

Lencioni T, Jonsdottir J, Cattaneo D, Crippa A, Gervasoni E, Rovaris M, Bizzi E, Ferrarin M.

Front Hum Neurosci. 2016 Dec 9;10:620. doi: 10.3389/fnhum.2016.00620. eCollection 2016.

25.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2016 Nov 24;11:CD009333. Review.

26.

6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis.

Racca V, Rovaris M, Vaini E, Cavarretta R, Ferratini M, Toccafondi A, Di Rienzo M.

J Am Coll Cardiol. 2016 Nov 1;68(18):2027-2029. doi: 10.1016/j.jacc.2016.08.032. No abstract available.

27.

B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.

Piancone F, Saresella M, Marventano I, La Rosa F, Zoppis M, Agostini S, Longhi R, Caputo D, Mendozzi L, Rovaris M, Clerici M.

Sci Rep. 2016 Jul 14;6:29699. doi: 10.1038/srep29699.

28.

White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis.

Bergsland N, Tavazzi E, Laganà MM, Baglio F, Cecconi P, Viotti S, Zivadinov R, Baselli G, Rovaris M.

J Neuroimaging. 2017 Jan;27(1):107-113. doi: 10.1111/jon.12364. Epub 2016 May 30.

PMID:
27239049
29.

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9.

30.
31.

A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial.

Cavalera C, Pagnini F, Rovaris M, Mendozzi L, Pugnetti L, Garegnani M, Molinari E.

Trials. 2016 Jan 4;17:4. doi: 10.1186/s13063-015-1136-9.

32.

Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances.

Ghezzi A, Mutta E, Bianchi F, Bonavita S, Buttari F, Caramma A, Cavarretta R, Centonze D, Coghe GC, Coniglio G, Del Carro U, Ferrò MT, Marrosu MG, Patti F, Rovaris M, Sparaco M, Simone I, Tortorella C, Bergamaschi R.

Neurol Sci. 2016 Mar;37(3):437-42. doi: 10.1007/s10072-015-2415-7. Epub 2015 Nov 27.

PMID:
26613723
33.

Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.

Racca V, Di Rienzo M, Cavarretta R, Toccafondi A, Vaini E, Ferratini M, Rovaris M.

Mult Scler. 2016 Apr;22(5):708-9. doi: 10.1177/1352458515600251. Epub 2015 Sep 10. No abstract available.

PMID:
26359278
34.

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis.

Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Fuchs D, Clerici M.

PLoS One. 2015 Jun 25;10(6):e0130715. doi: 10.1371/journal.pone.0130715. eCollection 2015.

35.

Fingolimod effects on left ventricular function in multiple sclerosis.

Racca V, Di Rienzo M, Cavarretta R, Toccafondi A, Vaini E, Ferratini M, Rovaris M.

Mult Scler. 2016 Feb;22(2):201-11. doi: 10.1177/1352458515587753. Epub 2015 Jun 3.

PMID:
26041795
36.

MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.

Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Clerici M.

J Transl Med. 2015 May 7;13:148. doi: 10.1186/s12967-015-0504-2.

37.

Corticospinal tract integrity is related to primary motor cortex thinning in relapsing-remitting multiple sclerosis.

Bergsland N, Laganà MM, Tavazzi E, Caffini M, Tortorella P, Baglio F, Baselli G, Rovaris M.

Mult Scler. 2015 Dec;21(14):1771-80. doi: 10.1177/1352458515576985. Epub 2015 Mar 19.

PMID:
25791368
38.

Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):1016-20. doi: 10.1136/jnnp-2014-309243. Epub 2014 Dec 30. Review.

PMID:
25550414
39.

Leishmaniasis: a disease with many names.

Nazzaro G, Rovaris M, Veraldi S.

JAMA Dermatol. 2014 Nov;150(11):1204. doi: 10.1001/jamadermatol.2014.1015. No abstract available.

PMID:
25389793
40.

Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study.

Tavazzi E, Laganà MM, Bergsland N, Tortorella P, Pinardi G, Lunetta C, Corbo M, Rovaris M.

Neurol Sci. 2015 Mar;36(3):371-7. doi: 10.1007/s10072-014-1954-7. Epub 2014 Sep 17.

PMID:
25228014
41.

An unusual photodistributed rash. Diagnosis: actinic varicella.

Rovaris M, Cambiaghi S, Gelmetti C.

Pediatr Dermatol. 2014 Sep-Oct;31(5):609-10. doi: 10.1111/pde.12366. No abstract available.

PMID:
25187387
42.

A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis.

Saresella M, Piancone F, Marventano I, La Rosa F, Tortorella P, Caputo D, Rovaris M, Clerici M.

FASEB J. 2014 Nov;28(11):5000-9. doi: 10.1096/fj.14-258194. Epub 2014 Aug 4.

PMID:
25091272
43.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2014 Jul 26;(7):CD009333. doi: 10.1002/14651858.CD009333.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 24;11:CD009333.

PMID:
25062935
44.

Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study.

Mancuso R, Franciotta D, Rovaris M, Caputo D, Sala A, Hernis A, Agostini S, Calvo M, Clerici M.

Mult Scler. 2014 Dec;20(14):1900-3. doi: 10.1177/1352458514538111. Epub 2014 Jun 16.

PMID:
24948690
45.

Determinants of disability in multiple sclerosis: an immunological and MRI study.

Tortorella P, Laganà MM, Saresella M, Tavazzi E, Preti MG, Ricci C, Baglio F, Marventano I, Piancone F, Baselli G, Cecconi P, Caputo D, Clerici M, Rovaris M.

Biomed Res Int. 2014;2014:875768. doi: 10.1155/2014/875768. Epub 2014 Apr 9.

46.

Drug therapy for multiple sclerosis.

Tavazzi E, Rovaris M, La Mantia L.

CMAJ. 2014 Aug 5;186(11):833-40. doi: 10.1503/cmaj.130727. Epub 2014 Apr 22. Review. No abstract available.

47.

Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.

Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, Furlan R.

J Immunol Res. 2014;2014:961863. doi: 10.1155/2014/961863. Epub 2014 Mar 26.

48.

The men or women behind nevi: Richard Sutton.

Nazzaro G, Rovaris M.

JAMA Dermatol. 2014 Mar;150(3):302. doi: 10.1001/jamadermatol.2013.9983. No abstract available.

PMID:
24623327
49.

Insights from magnetic resonance imaging.

Filippi M, Charil A, Rovaris M, Absinta M, Rocca MA.

Handb Clin Neurol. 2014;122:115-49. doi: 10.1016/B978-0-444-52001-2.00006-6. Review.

PMID:
24507516
50.

Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis.

Saresella M, Gatti A, Tortorella P, Marventano I, Piancone F, La Rosa F, Caputo D, Rovaris M, Biasin M, Clerici M.

Clin Immunol. 2014 Jan;150(1):109-20. doi: 10.1016/j.clim.2013.10.012. Epub 2013 Nov 5.

PMID:
24334148

Supplemental Content

Loading ...
Support Center